Oncology Reviews

, Volume 1, Issue 4, pp 205–214 | Cite as

The place of thalidomide in the treatment of multiple myeloma

Review
  • 23 Downloads

Abstract

Thalidomide represents the first attempt in multiple myeloma (MM) patients to overcome resistance to chemotherapy through a biological agent. The exciting results reported in the first study by Singhal et al. in 1999 [1] led to several other studies which aimed to evaluate its efficacy in different settings and disease phases, to define its toxicity, and to establish the optimal dose. Some of these questions have already been answered while others, such as the best dosage or the best schedule to obtain the highest efficacy with the lowest toxicity, still remain. Thalidomide has been studied as a single agent or in association with other drugs (dexamethasone, chemotherapy and new drugs) showing a synergic activity. We review the results of the main studies on the efficacy and toxicity of thalidomide used as a single agent or in association with other drugs, reflect on its present role, and consider its future contribution to the treatment of MM.

Key words

Thalidomide Multiple myeloma High-dose therapy Elderly patients 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571PubMedCrossRefGoogle Scholar
  2. 2.
    McBride WG (1961) Thalidomide and congenital abnormalities. Lancet II:1358CrossRefGoogle Scholar
  3. 3.
    Lenz W (1962) Thalidomide and congenital abnormalities. Lancet I:45CrossRefGoogle Scholar
  4. 4.
    Sheskin J (1965) Further observation with thalidomide in lepra reactions. Lepr Rev 36:183–187PubMedGoogle Scholar
  5. 5.
    D’Amato RJ, Loughan MS, Flynn E et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082–4085PubMedCrossRefGoogle Scholar
  6. 6.
    Kenyon BM, Browne F, D’Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse model of neovascolarization. Exp Eye Res 64:971–978PubMedCrossRefGoogle Scholar
  7. 7.
    Minchiton AI, Fryer KH, Wendt KR et al (1996) The effect of thalidomide on experimental tumors and metastases. Anti Cancer Drugs 7:339–343CrossRefGoogle Scholar
  8. 8.
    Or R, Feferman R, Shoshans S (1998) Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol 26:217–221PubMedGoogle Scholar
  9. 9.
    Rajkumar SV, Leong T, Roche PC (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 6:3111–3116PubMedGoogle Scholar
  10. 10.
    Neben K, Mohler T, Egerer G et al (2001) High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res 7:2675–2681PubMedGoogle Scholar
  11. 11.
    Neben K, Moehler T, Kraemer A et al (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 115:605–608PubMedCrossRefGoogle Scholar
  12. 12.
    Podar K, Tai YT, Davies FE et al (2001) Vascular endothelial growth factor triggers signalling cascades mediating multiple myeloma cell growth and migration. Blood 98:428–435PubMedCrossRefGoogle Scholar
  13. 13.
    Moreira AL, Sampaio EP, Zmuidzinas A et al (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675–1680PubMedCrossRefGoogle Scholar
  14. 14.
    Turk BE, Jian H, Liu JO (1996) Binding of thalidomide to alpha 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A 93:7552–7556PubMedCrossRefGoogle Scholar
  15. 15.
    Corral LG, Haslett PA, Muller GW et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380–386PubMedGoogle Scholar
  16. 16.
    Payvandi F, Wu L, Gupta D et al (2000) Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. Blood 96:579aGoogle Scholar
  17. 17.
    McHugh SM, Rifkin IR, Deighton J et al (1995) The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160–167PubMedGoogle Scholar
  18. 18.
    Haslett PA, Corral LG, Albert M et al (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885–1892PubMedCrossRefGoogle Scholar
  19. 19.
    Davies FE, Raie N, Hideshima T et al (2001) Thalidomide and immunomodulatory derivates augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210–216PubMedCrossRefGoogle Scholar
  20. 20.
    Parman T, Wiley MJ, Wells PG (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582–585PubMedCrossRefGoogle Scholar
  21. 21.
    Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96:2943–2950PubMedGoogle Scholar
  22. 22.
    Geitz H, Handt S, Zwingenberger K (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 31:213–221PubMedCrossRefGoogle Scholar
  23. 23.
    Barlogie B, Desikan R, Eddlemon P et al (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98:492–494PubMedCrossRefGoogle Scholar
  24. 24.
    Yakuob-agha I, Attal M, Dumonentet C et al (2002) Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the intergroupe Francophone du Myeloma (IFM). Hematol J 3:185–192CrossRefGoogle Scholar
  25. 25.
    Tosi P, Zamagni E, Cellini C et al (2002) Salvage therapy with thalidomide in patients with advance relapsed/refractory multiple myeloma. Haematologica 87:408–414PubMedGoogle Scholar
  26. 26.
    Leleu X, Magro L, Fawaz A et al (2002) Efficacy of low dose thalidomide in advanced multiple myeloma. Blood 100:1519–1520PubMedCrossRefGoogle Scholar
  27. 27.
    Pini M, Baraldi A, Pietrasanta D, et al (2000) Low-dose thalidomide in the treatment of refractory myeloma. Haematologica 85:1111–1112PubMedGoogle Scholar
  28. 28.
    Yakoub-agha I, Doyen C, Hulin C et al (2006) A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: results of the final analysis of the IFM01-02 study. J Clin Oncol 24(18s):7520 abstr.Google Scholar
  29. 29.
    Glasmacher A, Hahn C, Hoffmann F et al (2005) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 132:584–593CrossRefGoogle Scholar
  30. 30.
    Prince HM, Schenkel B, Mileshkin L (2007) An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 48:46–55PubMedCrossRefGoogle Scholar
  31. 31.
    Prince HM, Adena M, Kingsford Smith D et al (2007) Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. Eur J Haematol 79:93–99PubMedCrossRefGoogle Scholar
  32. 32.
    Richardson PG, Blood E, Mitsiades CS (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458–3464PubMedCrossRefGoogle Scholar
  33. 33.
    Cibeira MT, Rosinol L, Ramiro L et al (2006) Long term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol 77:486–492PubMedCrossRefGoogle Scholar
  34. 34.
    Richardson PG, Sonneveld P, Schuster M et al (2007) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110:3557–3560PubMedCrossRefGoogle Scholar
  35. 35.
    Corso A, Lorenzi A, Orlandi E et al (2002) Advantages of using thalidomide for the management of refractory myeloma patients. Haematologica 87:329–330Google Scholar
  36. 36.
    Corso A, Lorenzi A, Zappasodi P (2003) Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients. Haematologica 88:958–960PubMedGoogle Scholar
  37. 37.
    Weber DM, Gavino M, Delasalle K et al (1999) Thalidomide alone or with dexamethasone for multiple myeloma. Blood 94:604abstrGoogle Scholar
  38. 38.
    Palumbo A, Gaccone L, Bertola A et al (2001) Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 86:399–403PubMedGoogle Scholar
  39. 39.
    Palumbo A, Bertola A, Falco P et al (2004) Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 5:318–324PubMedCrossRefGoogle Scholar
  40. 40.
    Tosi P, Zamagni E, Cellini C et al (2004) Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Hematol 73:98–103CrossRefGoogle Scholar
  41. 41.
    Lee CK, Barlogie B, Munshi N et al (2003) DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 21:2732–2739PubMedCrossRefGoogle Scholar
  42. 42.
    Zangari M, Siegel E, Barlogie B et al (2002) Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100:1614–1615CrossRefGoogle Scholar
  43. 43.
    Dimopoulos MA, Hamilos G, Zomas A et al (2004) Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 5:112–117PubMedCrossRefGoogle Scholar
  44. 44.
    Offidani M, Bringhen S, Corvatta L et al (2007) Thalidomide, dexamethasone plus pegylated liposomal doxorubicin (ThaDD) vs thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol 78:297–302PubMedCrossRefGoogle Scholar
  45. 45.
    Ciolli S, Leoni F, Gigli F et al (2006) Low dose velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients. Leuk Lymphoma 47:171–173PubMedCrossRefGoogle Scholar
  46. 46.
    Terpos E, Anagnostopoulos A, Kastritis E et al (2005) The combination of Bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective treatment for relapsed/refractory myeloma: results of a phase II clinical trial. Blood 106:abstr 363Google Scholar
  47. 47.
    Palumbo A, Ambrosini MT, Benevolo P et al (2007) Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma. Blood 109:2767–2772PubMedGoogle Scholar
  48. 48.
    Rajkumar V, Hayman S, Gertz MA et al (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20:4319–4323PubMedCrossRefGoogle Scholar
  49. 49.
    Weber D, Rankin K, Gavino M et al (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16–19PubMedCrossRefGoogle Scholar
  50. 50.
    Hussein MA (2004) New treatment strategies for multiple myeloma. Semin Hematol 41:2–8PubMedCrossRefGoogle Scholar
  51. 51.
    Ghobrial IM, Dispensieri A, Bundy KL et al (2003) Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transpl 32:587–592CrossRefGoogle Scholar
  52. 52.
    Cavo M, Zamagni E, Tosi P et al (2005) Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106:35–39PubMedCrossRefGoogle Scholar
  53. 53.
    Zamagni E, Testoni N, Terragna C et al (2007) Incorporation of Thalidomide into up-front double autologous stem cell transplantation (ASCT) improves the outcome in comparison with double ASCT without thalidomide. Analysis of baseline factors predictive of outcome. Blood 110:abstr 447Google Scholar
  54. 54.
    Macro M, Divine M, Uzunhan Y et al (2006) Dexamethasone+Thalidomide (Dex/Thal) compared to VAD as a pretransplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. Blood 108:abstr 57Google Scholar
  55. 55.
    Kumar S, Lacy M, Dispenzieri A et al (2006) Analysis of outcome after autologous stem transplantation in patient with newly diagnosed myeloma: comparison of different induction regimens. Blood 108:abstr 3079Google Scholar
  56. 56.
    Barlogie B, Tricot G, Anaissie E et al (2006) Thalidomide and hematopoieticcell transplantation for multiple myeloma. N Engl J Med 354:1021–1030PubMedCrossRefGoogle Scholar
  57. 57.
    Zervas K, Dimopoulos MA, Hatzicharissi E et al (2004) Primary treatment of multiple myeloma with thalidomide, vincristine liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 15:134–138PubMedCrossRefGoogle Scholar
  58. 58.
    Barlogie B, Anaissie E, Rhee JH et al (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 138:176–185PubMedCrossRefGoogle Scholar
  59. 59.
    Offidani M, Corvatta L, Piersantelli MN et al (2006) Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 108:2159–2164PubMedCrossRefGoogle Scholar
  60. 60.
    Palumbo A, Bertola A, Musto P et al (2005) Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 104:1428–1433PubMedCrossRefGoogle Scholar
  61. 61.
    Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367:825–831PubMedCrossRefGoogle Scholar
  62. 62.
    Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus Melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma: a randomised trial. Lancet 370:1209–1218PubMedCrossRefGoogle Scholar
  63. 63.
    Rajkumar SV, Gertz MA, Lacy MA et al (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17:775–779PubMedCrossRefGoogle Scholar
  64. 64.
    Stewart AK, Chen CI, Howson-Jan K et al (2004) Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 10:8170–8176PubMedCrossRefGoogle Scholar
  65. 65.
    Feyler S, Rawstron A, Jackson G et al (2007) Thalidomide Maintenance following high dose therapy in multiple myeloma: a UK Myeloma Forum phase 2 study. Br J Haematol 139:429–433PubMedGoogle Scholar
  66. 66.
    Attal M, Harousseau JL, Leyvraz S et al (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289–3294PubMedCrossRefGoogle Scholar
  67. 67.
    Zangari M, Saghafifar F, Anaissie E et al (2002) Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 13:187–192PubMedCrossRefGoogle Scholar
  68. 68.
    Santos AB, Llamas P, Roman A et al (2003) Evaluation of thrombophylic states in multiple myeloma patients receiving thalidomide: a reasonable doubt. Br J Haematol 122:159–167PubMedCrossRefGoogle Scholar
  69. 69.
    Corso A, Lorenzi A, Terulla V, Airo F et al (2004) Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol 83:588–591PubMedCrossRefGoogle Scholar
  70. 70.
    Zangari M, Barlogie B, Anaissie E et al (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126:715–721PubMedCrossRefGoogle Scholar
  71. 71.
    Cavo M, Zamagni E, Cellini C et al (2002) Deep-vein thrombosysis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100:2272–2273PubMedCrossRefGoogle Scholar
  72. 72.
    Niesvizky R, Martinez-Banos D, Jalbrzikowski J et al (2007) Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatment of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 48:2330–2337PubMedCrossRefGoogle Scholar
  73. 73.
    Palumbo A, Rajkumar S, Dimopoulos MA et al (2007) Prevention of thalidomide and lenalidomide-associated thrombosis in myeloma. Leukemia doi:10.1038/sj.leu.2405062Google Scholar
  74. 74.
    Isoardo G, Bergui M, Durelli L et al (2004) Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand 109:188–193PubMedCrossRefGoogle Scholar
  75. 75.
    Cavaletti G, Beronio A, Reni L et al (2004) Thalidomide sensory neurotoxicity. A clinical and neurophysiologic study. Neurology 62:2291–2293PubMedGoogle Scholar
  76. 76.
    Tosi P, Zamagni E, Cellini C et al (2005) Neurological toxicity of long-term (<1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 74:212–216PubMedCrossRefGoogle Scholar
  77. 77.
    Plasmati R, Pastorelli F, Cavo M et al (2007) Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 69:573–581PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  1. 1.Division of HematologyPoliclinico San MatteoPaviaItaly
  2. 2.Division of Hematology, IRCCS Fondazione Policlinico San MatteoUniversity of PaviaPaviaItaly

Personalised recommendations